Pharmacokinetics of 5-aminolevulinic acid-induced protoporphyrin IX in skin and blood.
The fluorescence and photosensitivity of endogenously synthesized protoporphyrin IX (PPIX) is increasingly used for the diagnosis and treatment of malignant and certain non-malignant diseases. A selective accumulation of PPIX can be induced by application of 5-aminolevulinic acid (5-ALA), which is a precursor of PPIX in the cellular biosynthetic pathway of heme. The purpose of this study was to monitor the in vivo accumulation of PPIX in different locations of the skin after oral ingestion and to determine the pharmacokinetics of 5-ALA and PPIX in human blood plasma for various routes of application. At the same time we wanted to achieve an optimal treatment scheme but also study possible side-effects of 5-ALA administration. After oral application of 5-ALA in a concentration of 40 mg kg-1 body weight, the fluorescence intensities of PPIX in the skin showed maxima between 6.5 and 9.8 h depending on the location and decreased to values lower than 5% related to the maximum after a mean time of about 40 h. The measured absolute intensities of PPIX fluorescence varied strongly between different patients and different locations on one patient. In the plasma of blood samples, PPIX could be detected via its fluorescence for all studied routes of application with the exception of the ointment, where PPIX levels were below the detection limit of 1 microgram l-1. The highest mean concentration of 742 micrograms l-1 PPIX in the plasma was measured 6.7 h after oral application. For inhalation of 5-ALA, a mean maximum concentration of 12 micrograms l-1 could be detected 4.1 h after application, for intravesical instillation, the mean maximum concentration was found to be 1 microgram l-1 2.9 h after application. The kinetics of 5-ALA in the plasma peaked much earlier with a maximum concentration of 32 mg l-1 about 30 min. after oral administration. The 5-ALA levels did not exceed normal reference values after topical application. The results of our experiments suggest that for a systemic application of 5-ALA side-effects in sensitive patients cannot be excluded.
Rick
K
K
Department of Urology, University of Munich, Germany.
Sroka
R
R
Stepp
H
H
Kriegmair
M
M
Huber
R M
RM
Jacob
K
K
Baumgartner
R
R
D000368:Aged; D000622:Aminolevulinic Acid / Q000493:pharmacokinetics* / Q000494:pharmacology; D005453:Fluorescence; D006801:Humans; D008875:Middle Aged; D011524:Protoporphyrins / Q000493:pharmacokinetics*; D012867:Skin / Q000187:drug effects / Q000378:metabolism*
D011524:Protoporphyrins; D000622:Aminolevulinic Acid; C028025:protoporphyrin IX